BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17545589)

  • 1. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
    Tamura K; Furihata M; Chung SY; Uemura M; Yoshioka H; Iiyama T; Ashida S; Nasu Y; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Sci; 2009 May; 100(5):914-9. PubMed ID: 19298603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
    Uemura M; Tamura K; Chung S; Honma S; Okuyama A; Nakamura Y; Nakagawa H
    Cancer Sci; 2008 Jan; 99(1):81-6. PubMed ID: 17986282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
    Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
    Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
    Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
    Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation increases p300 expression in prostate cancer cells.
    Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
    Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
    Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
    Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
    Sirotnak FM; She Y; Khokhar NZ; Hayes P; Gerald W; Scher HI
    Mol Carcinog; 2004 Nov; 41(3):150-63. PubMed ID: 15390081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
    Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
    Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
    Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
    Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
    Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
    Mink SR; Hodge A; Agus DB; Jain A; Gross ME
    Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
    Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.